BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21398190)

  • 1. The effect of loose versus stranded seeds on biochemical no evidence of disease in patients with carcinoma of the prostate treated with iodine-125 brachytherapy.
    Herbert C; Morris WJ; Hamm J; Lapointe V; McKenzie M; Pickles T; Spadinger I; Keyes M
    Brachytherapy; 2011; 10(6):442-8. PubMed ID: 21398190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loose seeds versus stranded seeds in I-125 prostate brachytherapy: differences in clinical outcome.
    Hinnen KA; Moerland MA; Battermann JJ; van Roermund JG; Monninkhof EM; Jürgenliemk-Schulz IM; van Vulpen M
    Radiother Oncol; 2010 Jul; 96(1):30-3. PubMed ID: 20215039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes following iodine-125 brachytherapy in patients with Gleason 7, intermediate risk prostate cancer: a population-based cohort study.
    Herbert C; Morris WJ; Keyes M; Hamm J; Lapointe V; McKenzie M; Pickles T; Spadinger I
    Radiother Oncol; 2012 May; 103(2):228-32. PubMed ID: 22326573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conventional versus automated implantation of loose seeds in prostate brachytherapy: analysis of dosimetric and clinical results.
    Genebes C; Filleron T; Graff P; Jonca F; Huyghe E; Thoulouzan M; Soulie M; Malavaud B; Aziza R; Brun T; Delannes M; Bachaud JM
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):651-8. PubMed ID: 24138913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
    Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy.
    Heysek RV; Gwede CK; Torres-Roca J; Cantor A; Kelley S; Saini AS; Pow-Sang J
    Brachytherapy; 2006; 5(4):244-50. PubMed ID: 17118318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy.
    Hinnen KA; Battermann JJ; van Roermund JG; Moerland MA; Jürgenliemk-Schulz IM; Frank SJ; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1433-8. PubMed ID: 19540075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded-seed era?
    Kudchadker RJ; Swanson DA; Kuban DA; Lee AK; Bruno TL; Frank SJ
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):623-7. PubMed ID: 18410998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces?
    Thompson A; Keyes M; Pickles T; Palma D; Moravan V; Spadinger I; Lapointe V; Morris WJ
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):415-21. PubMed ID: 20133083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
    Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
    Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy.
    Potters L; Huang D; Fearn P; Kattan MW
    Brachytherapy; 2003; 2(1):26-31. PubMed ID: 15062160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate carcinoma patients upstaged by imaging and treated with irradiation. An outcome-based analysis.
    Pinover WH; Hanlon A; Lee WR; Kaplan EJ; Hanks GE
    Cancer; 1996 Apr; 77(7):1334-41. PubMed ID: 8608512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between preoperative and real-time intraoperative planning ¹²⁵I permanent prostate brachytherapy: long-term clinical biochemical outcome.
    Matzkin H; Chen J; German L; Mabjeesh NJ
    Radiat Oncol; 2013 Dec; 8():288. PubMed ID: 24341548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants.
    Prada PJ; Juan G; González-Suárez H; Fernández J; Jimenez I; Amón J; Cepeda M
    BJU Int; 2010 Jul; 106(1):32-6. PubMed ID: 20067460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Permanent implant brachytherapy for early, organ-confined prostate cancer].
    Agoston P; Major T; Fröhlich G; Baricza K; Szabó Z; Lövey J; Varjas G; Kásler M; Fodor J; Polgár C
    Magy Onkol; 2011 Sep; 55(3):170-7. PubMed ID: 21918742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel prostate brachytherapy technique: improved dosimetric and clinical outcome.
    Nobes JP; Khaksar SJ; Hawkins MA; Cunningham MJ; Langley SE; Laing RW
    Radiother Oncol; 2008 Jul; 88(1):121-6. PubMed ID: 18499289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer.
    Morris WJ; Keyes M; Palma D; McKenzie M; Spadinger I; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Lapointe V; Berthelet E; Pai H; Harrison R; Kwa W; Bucci J; Racz V; Woods R
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1432-8. PubMed ID: 19036530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.